228
Views
48
CrossRef citations to date
0
Altmetric
Review

Off-label use of hormones as an antiaging strategy: a review

, , &
Pages 1175-1186 | Published online: 23 Jul 2014

Abstract

Given demographic evolution of the population in modern societies, one of the most important health care needs is successful aging with less frailty and dependency. During the last 20 years, a multitude of anti-aging practices have appeared worldwide, aiming at retarding or even stopping and reversing the effects of aging on the human body. One of the cornerstones of anti-aging is hormone replacement. At present, women live one third of their lives in a state of sex-hormone deficiency. Men are also subject to age-related testosterone decline, but andropause remains frequently under-diagnosed and under-treated. Due to the decline of hormone production from gonads in both sexes, the importance of dehydroepiandrosterone (DHEA) in steroid hormone production increases with age. However, DHEA levels also decrease with age. Also, growth hormone age-associated decrease may be so important that insulin growth factor-1 levels found in elderly individuals are sometimes as low as those encountered in adult patients with established deficiency. Skin aging as well as decreases in lean body mass, bone mineral density, sexual desire and erectile function, intellectual activity and mood have all been related to this decrease of hormone production with age. Great disparities exist between recommendations from scientific societies and actual use of hormone supplements in aging and elderly patients. In this article, we review actual data on the effects of age related hormone decline on the aging process and age-related diseases such as sarcopenia and falls, osteoporosis, cognitive decline, mood disorders, cardiovascular health and sexual activity. We also provide information on the efficiency and safety of hormone replacement protocols in aging patients. Finally, we argue on future perspectives of such protocols as part of everyday practice.

Introduction

Antiaging medicine is a growing medical industry. The definition given by BinstockCitation1 for antiaging medicine is the following: “measures taken in order to slow, stop or even reverse phenomena related to aging, as well as to increase life span”. Various societies worldwide claim to have developed strategies against age-related diseases but also the aging process per se. One of the most important is the American Academy of Anti-aging Medicine, counting more than 26,000 members. Antiaging medicine was valued at around $20 billion in 2002 worldwide and constitutes an extremely fast-growing industry.Citation2

Successful aging is one of the most important needs of our fast-aging population. At present, worldwide numbers of people aged >60 years and >80 years reach 671 million and 80 million, respectively. Aging of the population is even more important in “developed” countries. Indeed, 21% of the European population and 17% of the North American population is aged >60 years.Citation2 When people aged >80 years are considered, half of them live in Europe and North America. These numbers are expected to rapidly grow. Estimates made by the United Nations World Population Prospects: The 2006 Revision (http://www.un.org/esa/population/publications/wpp2006/WPP2006_Highlights_rev.pdf) put the worldwide number of people aged >60 years and >80 years around 2 billion and 400 million, respectively, for 2050.Citation2 Therefore, the increase of the number of patients who will be referred to antiaging and geriatric programs is something to be expected. Perhaps the search for eternal youth will remain “factitious”. Nevertheless, most antiaging programs and clinics also seek to implement strategies for successful aging and disease prevention. Nobody could claim that successful aging is not an absolute necessity for our aging societies.

One of the cornerstones of antiaging practices is hormone replacement. Hormone decrease with age is common and is related to decreased secretion from the pituitary gland, adrenals, and gonads.Citation3 Skin aging as well as decreases in lean body mass, bone mineral density (BMD), sexual desire and erectile function, intellectual activity, and mood have all been related to this decrease in hormone production with age.Citation3Citation5 This has led to the rather wide off-label use of hormone supplements in order to help reverse the effects of aging and improve quality of life. Unfortunately, studies on specific indications, long-term effects, and risks of such practices are lacking. In this article we will review actual data on the most frequently used hormones in antiaging medicine, their relationship with age-related diseases, and the safety of hormone supplementation protocols.

Estrogens and progestins

Symptoms of menopause such as vasomotor symptoms or vaginal dryness and reduced sexual pleasure affect two-thirds of women during perimenopause.Citation6,Citation7 In 10%–15% of cases the intensity of symptoms is such that they interfere with daily activities and sleep.Citation7 Demand for treatments that may reduce such symptoms is important. Estrogens alone or together with progesterone can relieve climacteric symptoms, increase quality of life, and prevent or even reverse vaginal atrophy. Despite estrogens’ positive effects on symptoms, as well as on bone loss and colorectal cancer risk,Citation8Citation11 the Women’s Health Initiative (WHI) studyCitation12 showed a higher risk for breast cancer, stroke, cardiovascular disease, and thromboembolic events with combined treatment of estrogens and progestin. Nevertheless, several positive effects of hormone replacement therapy (HRT) were observed in this study. For instance, the combination of estrogen and progestin reduced by one-third the rates of hip and clinical vertebral fractures. Endometrial cancer rates were not influenced by the treatment, whereas colorectal cancer rates were reduced by 37%. Total cancer incidence was not affected. In women with unopposed estrogen treatment, breast cancer risk did not increase.

The WHI study influenced overall prescription of HRT, notwithstanding that it used a very specific combination and dosage of conjugated equine estrogens and medroxyprogesterone acetate. It is therefore far from certain that the study’s findings apply to lower dosages or other hormone formulations.Citation13

Following these results, actual guidelines recommend that HRT be used at the lowest dose for the shortest amount of time. The US Food and Drug Administration proposes HRT only for vaginal dryness and hot flashes.Citation14 Due to positive effects on bone, it may also be used exceptionally for the prevention of osteoporosis when other treatments are considered inappropriate.Citation8,Citation15

Physicians and patients have become extremely reluctant concerning HRT following the WHI study. Numbers of HRT prescriptions in the US rose from 58 million in 1995 to 90 million in 1999, corresponding to 15 million women per year. Numbers remained stable through to 2002. Within 3 months after publication of the results of the WHI study, prescriptions of various formulations of combined estrogens and progesterone dropped by 33% to 66%.Citation13 On the other hand, it has been estimated that 30% of women turn to alternative therapies to treat menopausal symptoms.Citation16 Nowadays, multiple sites and books promote more natural ways for HRT using “bioidentical” products. Women worldwide are subject to increasing publicity on bioidentical estradiol, the less potent estrogen estriol, and bioidentical progesterone.

There is no standardized definition for the term “bioidentical”.Citation17 Bioidentical hormones are supposed to have the same molecular structure as endogenous hormones found in humans. They are most frequently produced from plants (mostly soy or yams) and are biochemically altered to be identical to hormones found in the body.Citation8 They include estradiol, estrone, estriol, and progesterone and exist as compounded products or in regular approved drugs. Two other groups of estrogens are used in HRT and are considered to be nonbioidentical: natural estrogens found in the urine of pregnant mares (estrone sulfate and equilin sulfate) and synthetic estrogens (ethinyl estradiol and quinestrol).Citation8 Synthetic progestins mostly used worldwide include medroxyprogesterone acetate (most frequently used in the US), norethidrone acetate, cyproteron acetate, norgestimate, norgestrel, and dydrogesterone.

Estradiol

Estradiol is the most potent estrogen in women. Bioidentical estradiol is available in pills, patches, transdermal formulations, and vaginal gels. Various factors influence the efficiency and safety profile of estradiol, such as administration route, posology, age at which treatment was initiated, as well as the type of progestin used in combination.Citation8,Citation18 In general, transdermal estradiol formulations seem as effective as oral formulations, but studies have shown better safety profiles. First, concerning thromboembolism risk, transdermal estradiol avoids the “first-pass” effect, thus minimizing the induction of clotting factors by the liver. It therefore seems to have a lower risk for thromboembolism than oral estrogens.Citation19,Citation20 Concerning cardiovascular risk safety, the first-pass effect also appears to be associated with better lipid profiles.Citation19 Oral estrogen formulations would also be responsible for the production of angiotensinogen by the liver. Nevertheless, an increased risk for high blood pressure with oral formulations or a beneficial effect of transdermal estradiol on blood pressure has not been confirmed in clinical studies.Citation19,Citation21 Moreover, transdermal estradiol improved endothelial function in postmenopausal women with coronary artery disease when compared with placebo.Citation22 Finally, transdermal estradiol formulations seem to have a better effect on the prevention of atherosclerosis.Citation23 Of course, concerning cardiovascular risk, timing of HRT introduction is crucial, and positive effects are mostly observed when treatment is introduced around perimenopause.Citation19

Concerning breast cancer, WHI showed an increased risk only in the group where estrogens were combined with progestins, whereas unopposed estrogen treatment was not related to an increase of breast cancer risk.Citation12 Concerning opposed treatment, observational data support a better safety profile for breast cancer with the combination of bioidentical estradiol and bioidentical progesterone compared with the combination used in the WHI study (conjugated equine estrogen and medroxyprogesterone acetate).Citation19 Also, transdermal estradiol formulations have been related to better safety profiles than oral formulations.Citation24 In fact, various estrogen metabolites have different effects on breast cancer risk. 4-Hydroxyestrogens and 16α-hydroxyestrone are related to a higher risk, whereas 2-methoxyestradiol has mostly anticarcinogenic effects.Citation25 Oral estrogen formulations have been related to higher levels of potentially toxic estrogen metabolites compared with transdermal estradiol.Citation26 Nevertheless, others found no differences between estradiol administration routes and the risk for breast cancer.Citation27,Citation28

Estriol

Estriol is widely used in antiaging medicine as an HRT. Estradiol is reversibly transformed to estrone.Citation6 On the other hand, estriol is the irreversible end product of estradiol and estrone metabolism.Citation8 There are two kinds of estrogen receptors (ERs) in tissue, ER-α and ER-β. Estradiol has equally high affinity for both. Estrone, on the other hand, has a lower overall affinity than estradiol but is still rather high (around two-thirds of estradiol’s affinity for ER-α and one-third for ER-β). Estriol is a weaker estrogen with only one-seventh of estradiol’s affinity for ER-α and one-fifth for ER-β. ER-α receptors are mostly encountered in the ovaries, the endometrium, and breast cancer cells, whereas ER-β is mostly found in the intestine, kidney, lung, bone, bone marrow, brain, and endothelium.Citation29 Use of estriol in antiaging medicine is based on the fact that it is a weak estrogen and potentially safer in terms of breast cancer. Theoretically, lower estrogenic activity on tissue such as the breast and the endometrium should be related to lower cancer risk. Nevertheless, affinity of receptors does not completely correspond to estrogenic activity at a tissue level.Citation29 Despite it being considered a weak estrogen, oral (but not vaginal) estriol has a proliferative effect on endometrial tissue, exposing women to a higher risk for endometrial cancer.Citation30 Moreover, studies on the effect of estriol on breast tissue in humans have been inconsistent.Citation6 Thus, estriol administration (regardless of the route) has been related to higher risks for lobular but not tubular or ductal breast cancer.Citation31 Others found no relationship between short- and long-term use of estriol (over 5 years) and breast cancer incidence.Citation27

It would be rather premature to state that estriol is a safe alternative to classic HRT, and further studies are necessary. Regarding its efficiency, positive effects of estriol on vaginal, urinary, and climacteric symptoms have been reported in several studies.Citation32Citation36 A slight increase in BMD was reported in an open-label studyCitation34 but has not been confirmed by others.Citation33,Citation36

Progesterone

In order to counter estrogen’s proliferative effect on the endometrium, nonhysterectomized women should also be administered progesterone. Antiaging specialists put forward the benefits of bioidentical progesterone treatment compared with synthetic progestins regarding efficiency and safety. Indeed, synthetic progestins may have different affinities for hormone receptors (androgen, progesterone, glucocorticoid, mineralocorticoid, estrogen, and growth hormone [GH]) and thus different effects on target tissue that are difficult to foresee and control.Citation37Citation39 Bioidentical progesterone produced from yams or soybeans is available worldwide. It is usually micronized in order to increase oral bioavailability.Citation6 A total of 200 mg daily for 12 days per month efficiently inhibits estrogen’s effect on the endometrium.Citation6

Oral bioidentical progesterone, when combined with estradiol, improves sleep quality more efficiently than synthetic medroxyprogesterone acetate.Citation7 Moreover, a positive effect of bioidentical progesterone on the bone (inhibition of the decrease in trabecular number, enhancement of mineral apposition, and bone formation) has been shown in animal studies.Citation40 Additionally, cardiovascular safety profile seems better with bioidentical progesterone compared with synthetic progestins.Citation19,Citation37 Indeed, a more positive effect of bioidentical progesterone compared with synthetic progestins on blood pressure, through an antimineralocorticoid effect, has been put forward.Citation19,Citation37 Also, bioidentical progesterone blunts to a lesser degree the positive effects of estrogens on HDL, compared with synthetic progestins.Citation41 Moreover, contrarily to synthetic progestins, when combined with transdermal estradiol, bioidentical progesterone does not increase the risk for venous thromboembolic events.Citation20 Finally, a lower risk for breast cancer has been reported with bioidentical progesterone compared with synthetic progestins.Citation28,Citation42 In general, oral bioidentical progesterone seems to be more efficient and safer than synthetic progestins.

On the other hand, data on potential benefits of transdermal bioidentical progesterone remain inconsistent.Citation6 Some report that bypassing the “first-pass” liver effect, which is responsible for metabolizing approximately 90% of progesterone ingested, may actually help avoid side effects due to metabolites, such as drowsiness.Citation37 Nevertheless, the efficiency of transdermal and vaginal routes remains a matter of discussion, some reporting identical and more stable progesterone levels with these formulations and others an insufficient effect for treating menopause-related symptoms but also for preventing endometrial proliferation and hyperplasia.Citation37,Citation43,Citation44 Such forms need to be validated in large-scale studies regarding their efficiency and safety before they may be proposed as standard treatment.

Antiaging specialists promote the use of bioidentical hormones as a more natural way to supplement hormone deficiencies in postmenopausal women. In theory, it is very attractive to be able to supplement with a hormone compound that is identical to the one lacking. Indeed, hormones participate in most of the body’s functions in different degrees, and hormone analogs may only partially fulfil the multiple roles of the natural hormone. Preliminary studies seem to support a better safety profile of bioidentical hormones, but this should be confirmed by large-scale studies. Also, further studies are necessary that directly compare synthetic hormones with bioidentical hormones, in terms of efficiency and safety.

Testosterone

Testosterone (T) is the major circulating hormone in men, but it is also present, to a lower degree, in women. It is produced by Leydig cells in men, whereas in postmenopausal women its production is mostly dependent on transformation from dehydroepiandrosterone (DHEA) through intracrine mechanisms.Citation45,Citation46 In men, 44% of circulating T is bound to a transport protein, the sex hormone-binding globulin (SHBG). Another 50% is bound to albumin, 4% to cortisol-binding globulin, and 2% remains free. Active or bioavailable T includes free and albumin-bound T (as albumin’s affinity for T is 1,000 times lower compared with SHBG).Citation47Citation49

Total T decreases with age at a rate of 0.4%–1% per year.Citation50Citation52 This results in a 20% and 30%–50% prevalence of low total T levels in men aged >60 years and >80 years, respectively.Citation5,Citation53 Andropause or late onset male hypogonadism diagnosis requires both the presence of symptoms and low T plasma levels.Citation5 The prevalence of andropause is increasing with age, reaching 5% in patients aged between 70 years and 79 years.Citation5

Effects of testosterone decline on the aging process and age-related diseases

Low T has been related to various age-associated conditions.Citation5 Low muscle massCitation54,Citation55 and strength,Citation54 as well as worse functional status,Citation56 are more frequent in elderly men with low T plasma levels. Moreover, low T, together with alcohol and glucocorticoids, is one of the most frequent causes of osteoporosis in older men.Citation57 Studies have also suggested a relationship between low T levels, mild cognitive impairment, and Alzheimer’s disease.Citation58,Citation59

Efficiency and safety of testosterone supplementation

T supplementation has been studied in aging populations regarding age-related conditions. Thus, T replacement therapy is beneficial for sarcopeniaCitation55,Citation56,Citation60 and bone density in older men.Citation61,Citation62 Concerning cognitive function, T supplementation has positive effects on verbal, spatialCitation63Citation65 and working memory,Citation66 visuospatial function,Citation67Citation69 and executive function.Citation70

Contrary to the widespread belief that T is related to a higher cardiovascular risk, studies show that atherosclerosis is mostly related to low T levels.Citation71Citation77 Moreover, direct antianginal effects have been described with T administration.Citation78,Citation79 Nevertheless, an increase of adverse cardiovascular effects with T administration has also been described. Treatment should not be initiated in patients with recent ischemic heart disease or heart failure.Citation80,Citation81

One of the main concerns with T supplementation is polycythemia. Indeed, an increase of hematocrit following T treatment is fairly frequent, mostly with intramuscular formulations and in older populations.Citation82,Citation83 For this reason, a follow-up of hematocrit levels every 6 months for 18 months and yearly thereafter should always be planned when T treatment is introduced. If hematocrit exceeds 52%–55%, treatment should be decreased or discontinued.Citation5

Ever since animal studies reported prostate cancer growth stimulation by T administration,Citation84 concerns have been put forward about the role of T in promoting or accelerating the development of prostate cancer in humans. Nevertheless, most recent studies have failed to confirm a relationship between T levels and the risk for prostate cancer.Citation85Citation87 On the contrary, increased risk for prostate cancer onset, higher 5-year biochemical relapse rates, and higher Gleason scores were associated with low T plasma levels.Citation85,Citation88 Concordantly, the T supplementation safety profile is rather satisfying regarding prostate cancer risk,Citation82,Citation83,Citation89Citation92 even for patients after treatment for prostate cancer by radical prostatectomy,Citation89 brachytherapy,Citation93 or external beam radiation.Citation94 Of course, active prostate cancer formally prohibits T treatment. Finally, follow-up of low urinary tract symptoms and prostate-specific antigen (PSA) levels is mandatory.Citation82,Citation92

T administration for andropause treatment should follow very strict rules concerning the choice of the patient to treat, as well as the follow-up of different parameters such as PSA and hematocrit.Citation5 When a male presents with symptoms of hypogonadism, a total T measure should be taken. Free T should be measured either when total T levels are close to the lower limit of normal values or in situations where SHBG alterations may be suspected (treatment with progestins, estrogens, anticonvulsivants, or glucocorticoids, as well as conditions such as HIV infection, thyroid disorders, acromegaly, nephritic syndrome, diabetes mellitus, and liver cirrhosis). Pretreatment control should include a detailed history for congestive heart failure, coronary disease, sleep apnea, low urinary tract symptoms, and prostate carcinoma. A digital prostate examination should be carried out and PSA blood levels should be checked. In case of an abnormal clinical examination or PSA levels >4 ng/mL (or PSA >3 ng/mL in men at high risk), a transrectal ultrasound-guided prostate biopsy should be performed. T supplementation should not be started in cases of suspected prostate cancer, severe symptoms of low urinary tract (International Prostate Symptom Score >19), hematocrit >50%, poorly controlled congestive heart failure, ischemic heart disease in the preceding 6 months, or untreated sleep apnea. In general, studies concur that if T is used according to international guidelines and plasma levels do not reach supraphysiologic levels, serious adverse effects are rare.Citation95

Future perspectives of testosterone supplementation

Label use of T supplementation in the US as well as in most European countries concerns only male hypogonadism. Unfortunately, it is also widely used as an anabolic steroid for its effects on muscle mass. On the other hand, T is also underused. Partly because of widespread concerns about T treatment safety, only 5% of men in the US with hypogonadism receive appropriate treatment.Citation91 It is therefore vital that physicians treating patients at high risk for male hypogonadism, such as elderly patients, are well aware of the benefits, risks, and treatment modalities of T supplementation. Indeed, its positive effects on bone and muscle could make T extremely interesting in geriatric rehabilitation protocols. Its role in cognitive and mood disorder treatment is yet to be defined. Finally, studies are progressively appearing concerning its use in chronic diseases related to sarcopenia and cachexia, such as chronic obstructive pulmonary disease.Citation96

Dehydroepiandrosterone

DHEA is a steroid prohormone produced by the adrenal glands and transformed in target tissue through intracrine mechanisms to androgens or estrogens. Plasma DHEA levels decline with age. By the age of 70–80 years, levels may be as low as 10%–20% of those encountered in young individuals.Citation46

The importance of DHEA in steroid hormone production increases with age.Citation4 Indeed, in postmenopausal women, production of estrogens by the ovaries declines dramatically, making the adrenals the only source of steroid hormones through DHEA.Citation97,Citation98 In men, although T secretion by the testicles continues late into life, T levels progressively decline, and DHEA’s importance in steroid hormone production is also higher with increasing age. DHEA’s effect is mostly through its hormone end products. Nevertheless, in vitro studies have shown that DHEA may directly increase nitric oxide production from intact endothelial cells, probably through G protein-dependent activation of endothelial nitric oxide synthetase, thus supporting proper intrinsic physiological functions.Citation99

Effects of DHEA decline on the aging process and age-related diseases

DHEA decline with age is clinically relevant and has been related to a variety of age-related conditions.Citation4 A positive relationship between DHEA levels and muscle mass, muscle strength, as well as mobility and a lower risk for falls, has been described in elderly individuals.Citation100Citation103 Moreover, a positive effect of DHEA on BMD through transformation to estrogens (in vitro human osteoblasts present an aromatase activity),Citation104 but also directly through mitogen-activated protein kinase signaling pathways, has been suggested.Citation105 Indeed, DHEA levels have been positively related to BMD in womenCitation104 and men.Citation106

Concerning neuropsychiatric diseases, the relationship between DHEA and cognitive disorders has not been studied sufficiently in order to formally conclude on its effect on dementia onset and progression.Citation4 On the other hand, the relationship between DHEA levels and mood disorders seems clearer. Low levels of DHEA have been related to depression symptoms.Citation107,Citation108

The relationship between DHEA levels and cardiovascular disease risk factors such as cholesterol and glucose tolerance is inconsistent.Citation4 Nevertheless, studies have shown that low DHEA levels are related to a higher risk for atherosclerosis,Citation109Citation112 heart failure,Citation113,Citation114 cardiovascular complications, and overall mortality.Citation115,Citation116

DHEA seems to play a rather important role in sexual function for both sexes. Low levels of DHEA were related to a higher risk for erectile dysfunction in menCitation117Citation119 and low sexual responsiveness in women.Citation45,Citation120

Efficiency and safety of DHEA supplementation

DHEA administration has had positive effects on muscle mass and strength, as well as physical performance parameters.Citation121Citation125 Also, DHEA has had positive effects on BMD both in womenCitation122,Citation126Citation130 and in men.Citation122,Citation128,Citation129,Citation131,Citation132 Furthermore, DHEA supplementation has shown positive effects on moodCitation133Citation137 as well as sexual function both for menCitation133,Citation138 and for women.Citation139Citation143 However, no positive effects on erectile function were found when conditions such as diabetes or neurological disorders were present.Citation144 Finally, DHEA supplementation has improved menopause symptoms in perimenopausal and early postmenopausal women.Citation140,Citation145,Citation146 Also, intravaginal formulations have had a positive effect in reversing vaginal mucosa atrophy in postmenopausal women.Citation146

Most studies show a very satisfying safety profile for DHEA supplementation. Only minimal effects such as mild acne, seborrhea, facial hair growth, and ankle swelling have been reported in women.Citation147,Citation148 Otherwise, DHEA supplementation has had a rather positive effect on skin.Citation139 No significant effect has been reported on hormone-dependent tumors such as breast and prostate cancer.Citation97,Citation132 On the contrary, animal studies showed that DHEA inhibits tumors of lymphatic tissue, lung, colon, breast, liver, and skin.Citation149,Citation150 Nevertheless, to our knowledge, the longest study durations for DHEA supplementation did not exceed 2 years. Consequently, no data exist on treatment safety regarding hormone-dependent tumors (breast, prostate, and endometrium), cardiovascular risk, or mortality for longer treatments.

Future perspectives of DHEA supplementation

DHEA has the status of a dietary supplement and is sold over the counter in the US. In Europe, in most countries it is either forbidden (France) or subject to medical prescription (Switzerland). DHEA is widely used in antiaging medicine and is considered as a “fountain of youth” hormone by some. As it is a prohormone, it is also used as a “hormone regulator”, permitting the body to reach a hormone equilibrium. DHEA is indeed a prohormone with positive effects on several age-related diseases. Supplementing a prohormone is also extremely interesting, as it would theoretically provide the organism with the possibility to use it and transform it according to local and general hormone needs. For the future, the role of DHEA supplementation in specific indications such as sarcopenia, falls and rehabilitation protocols, osteoporosis, mood and cognitive disorders, and also sexual well-being needs to be better studied in longer and larger studies. Finally, physicians prescribing DHEA should consider and inform their patients of the fact that long-term effects concerning efficiency, but also safety, are still uncertain.

Growth hormone

GH is widely used in antiaging medicine in order to reverse the effects of aging. GH levels decrease with age.Citation151 This decrease may be so important that insulin growth factor-1 (IGF-1) levels found in elderly individuals are as low as those encountered in adult patients with established GH deficiency.Citation152,Citation153 Multiple factors may influence GH decrease, but it seems mostly related to a decrease in GH-releasing hormone secretion together with higher somatostatin secretion levels. GH decrease combined with the fact that frailty and aging share several characteristics with GH deficiency encountered in younger adults (increase of fat mass and decrease of lean mass, cognitive impairment, psychological difficulties, dry and thin skin, and impaired cardiac capacity)Citation154 have made it rather popular in antiaging medicine.

Effects of GH decline on the aging process and age-related diseases

The effect of GH on longevity and whether GH is a proaging or antiaging hormone is a matter of controversy. Animal studies in which interventions reduced GH and IGF-1 levels or increased resistance to GH resulted in an increased life span.Citation155,Citation156 Concordantly, age-related cognitive alterations and decreased life span were encountered in animal models producing supraphysiological levels of GH. Potential underlying mechanisms of low GH effects include reduced oxidative metabolism and lower oxidative stress, increased stress resistance, and enhanced sensitivity to insulin.Citation157 In humans, recent studies on Ecuadorian individuals who carry mutations in the GH receptor gene, leading to severe GH receptor and IGF-1 deficiencies, showed a decreased incidence of malignancies as well as diabetes, compared with control subjects. Higher insulin sensitivity in this population as well as higher antioxidant capacities were reported.Citation158 Others reported associations between GH deficiency or GH resistance and increased longevity, better lipid profiles, less atherosclerosis and vascular pathology, as well as a decreased risk for developing cancer.Citation159Citation162

As a matter of fact, both too high and too low levels of GH and IGF-1 seem to be associated with reduced longevity in humans.Citation152 Thus, others reported reduced longevityCitation163 as well as higher cardiovascular risk and higher cardiovascular and cerebrovascular mortality in GH-deficient patients.Citation164,Citation165 Concerning osteoporosis, low IGF-1 levels have been related to lower BMD in men.Citation166,Citation167 GH and IGF-1 receptors are present in multiple areas of the human brain (hippocampus, superficial and deep cortical layers, olfactory bulb, thalamus, and amygdala).Citation168Citation170 In humans, one longitudinal study found a correlation between low total but not free IGF-1 levels and incident decline in Mini Mental State Examination scores after an average 1.9-year follow-up in a group of 186 individuals aged between 55 years and 80 years.Citation170 Another study showed a positive correlation between IGF-1 levels and Mini Mental State Examination scores in a group of 22 individuals aged between 65 years and 86 years.Citation171 Unfortunately, very few studies have explored the effects of GH on cognition, and most of them are small and rather short. To our knowledge, none has studied the relationship between somatotropic status and the risk for dementia in elderly populations.

Efficiency and safety of GH supplementation

The effect of GH supplementation on age-related diseases has been studied. Potential positive effects of GH treatment concern body composition, with an increase in lean mass and a decrease in fat tissue.Citation172,Citation173 Nevertheless, this increase in muscle mass was not always related to an improved physical ability.Citation172,Citation174 The possibility that higher measures of lean mass may be related to increased fluid retention has been put forward.Citation152,Citation175 Studies on the effects of GH supplementation on BMDCitation152,Citation176 as well as on lipid profile and glucose metabolism have been rather inconsistent.Citation176

Concerning cognitive disorders, animal studies showed that restoring IGF-1 levels in transgenic mice with Alzheimer’s disease decreased αβ-amyloid accumulation, a hallmark neuropathological lesion of Alzheimer’s disease.Citation177 In humans, treatment with GH-releasing hormone analogs improved cognition in healthy elderly individuals but also in patients with mild cognitive impairment.Citation177,Citation178 Also, a 1-year GH supplementation had positive effects on cognitive performance of elderly patients with GH deficiency.Citation179 Further studies are necessary in order to formally conclude on the potential effect of GH supplementation on cognitive function and, more specifically, on dementia risk.

The safety of GH supplementation in aging individuals is still a matter of debate. No increase in the risk for cancer with GH supplementation has been reported in young patients with overt deficiency.Citation180 In older patients with age-related GH deficiency, short-term clinical trials observed no increase of cancer incidence or deaths,Citation152 but no data exist for long-term treatments. Moreover, studies in healthy elderly have shown a higher risk for adverse effects of GH supplementation, such as carpal tunnel syndrome, gynecomastia, and fluid retention. Concerns have also been put forward about a dose-dependent increase of insulin resistance with GH treatment.Citation176

Future perspectives of GH supplementation

Despite clear positive effects in GH-deficient patients, GH supplementation in antiaging medicine for healthy elderly individuals with low GH levels due to age is still a matter of debate, with unclear pros and cons.Citation181 Further studies are required regarding specific indications and the long-term safety and efficiency of such treatments.

Conclusion

Hormone level decline is a part of aging. It is not yet clear whether this decline should be considered as a physiologic reaction of the body to aging and thus a part of “normal” or “healthy” aging or whether actively treating it would actually help to prevent and treat serious or even life-threatening age-related conditions. We strongly believe that hormones should be a part of geriatric care. Nevertheless, “countering aging effects” is too general as an indication, is subject to confusion, and cannot be a basis for treatment. Large-scale studies are necessary in order to better define precise indications and treatment modalities in aging and elderly individuals. In-depth assessments of hormone needs and precise follow-up plans should be elaborated for everyday clinical practice. Finally, once hormone supplementation is installed, treatment may last for years or decades. Long-term or very long-term safety of such treatments should also be a matter of study.

Disclosure

The authors report no conflicts of interest in this report.

References

  • BinstockRHAnti-aging medicine and research: a realm of conflict and profound societal implicationsJ Gerontol A Biol Sci Med Sci200459B523B53315215257
  • StuckelbergerAAnti-ageing Medicine. Myths and Chances1st edZürich, SwitzerlandHochschulverlag2008
  • ZouboulisCCMakrantonakiEHormonal therapy of intrinsic agingRejuvenation Res20121530231222533363
  • SamarasNSamarasDFrangosEForsterAPhilippeJA review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial?Rejuvenation Res201316428529423647054
  • SamarasNSamarasDLangPOA view of geriatrics through hormones. What is the relation between andropause and well-known geriatric syndromes?Maturitas2013743213219
  • SitesCKBioidentical hormones for menopausal therapyWomens Health (Lond Engl)2008416317119072518
  • MontplaisirJLorrainJDenesleRPetitDSleep in menopause: differential effects of two forms of hormone replacement therapyMenopause20018101611201509
  • CiriglianoMBioidentical hormone therapy: a review of the evidenceJ Womens Health (Larchmt)20071660063117627398
  • MacLennanALesterSMooreVOral oestrogen replacement therapy versus placebo for hot flushesCochrane Database Syst Rev20011CD00297811279791
  • CauleyJARobbinsJChenZEffects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trialJAMA20032901729173814519707
  • RymerJMorrisEPExtracts from “Clinical Evidence”: menopausal symptomsBMJ20003211516151911118182
  • RossouwJEAndersonGLPrenticeRLRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trialJAMA200228832133312117397
  • HershALStefanickMLStaffordRSNational use of postmenopausal hormone therapy: annual trends and response to recent evidenceJAMA2004291475314709575
  • Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of The North American Menopause SocietyMenopause20071416818217259911
  • EttingerBEnsrudKEWallaceREffects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trialObstet Gynecol200410444345115339752
  • KaufertPBoggsPPEttingerBWoodsNFUtianWHWomen and menopause: beliefs, attitudes, and behaviors. The North American Menopause Society. 1997 Menopause SurveyMenopause199851972029872483
  • FilesJAKoMGPruthiSBioidentical hormone therapyMayo Clin Proc20118667368021531972
  • Coelingh BenninkHJAre all estrogens the same?Maturitas20044726927515063479
  • L’HermiteMSimonciniTFullerSGenazzaniARCould transdermal estradiol + progesterone be a safer postmenopausal HRT? A reviewMaturitas20086018520118775609
  • CanonicoMOgerEPlu-BureauGHormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER studyCirculation200711584084517309934
  • SchunkertHDanserAHHenseHWDerkxFHKurzingerSRieggerGAEffects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal womenCirculation19979539458994414
  • BlumelJECastelo-BrancoCLealTEffects of transdermal estrogens on endothelial function in postmenopausal women with coronary diseaseClimacteric20036384412725663
  • Le GalGGourletVHogrelPPlu-BureauGTouboulPJScarabinPYHormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) studyAtherosclerosis200316616317012482563
  • OpatrnyLDell’AnielloSAssoulineSSuissaSHormone replacement therapy use and variations in the risk of breast cancerBJOG2008115169175 discussion 7518081598
  • LippertCSeegerHMueckAOThe effect of endogenous estradiol metabolites on the proliferation of human breast cancer cellsLife Sci20037287788312493568
  • MueckAOSeegerHBreast cancer: are estrogen metabolites carcinogenic?Climacteric200710Suppl. 2626517882675
  • LyytinenHPukkalaEYlikorkalaOBreast cancer risk in postmenopausal women using estrogen-only therapyObstet Gynecol20061081354136017138766
  • FournierABerrinoFClavel-ChapelonFUnequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort studyBreast Cancer Res Treat200810710311117333341
  • KuiperGGCarlssonBGrandienKComparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and betaEndocrinology19971388638709048584
  • WeiderpassEBaronJAAdamiHOLow-potency oestrogen and risk of endometrial cancer: a case-control studyLancet19993531824182810359406
  • RosenbergLUMagnussonCLindstromEWedrenSHallPDickmanPWMenopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control studyBreast Cancer Res20068R1116507159
  • IosifCSEffects of protracted administration of estriol on the lower genito urinary tract in postmenopausal womenArch Gynecol Obstet19922511151201605675
  • TakahashiKManabeAOkadaMKuriokaHKanasakiHMiyazakiKEfficacy and safety of oral estriol for managing postmenopausal symptomsMaturitas20003416917710714912
  • MinaguchiHUemuraTShirasuKEffect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open studyJ Obstet Gynaecol Res1996222592658840712
  • RazRStammWEA controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infectionsN Engl J Med19933297537568350884
  • YangTSTsanSHChangSPNgHTEfficacy and safety of estriol replacement therapy for climacteric womenZhonghua Yi Xue Za Zhi (Taipei)1995553863917641124
  • MoskowitzDA comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risksAltern Med Rev20061120822317217322
  • Sitruk-WareRPharmacological profile of progestinsMaturitas20044727728315063480
  • Sitruk-WareRProgestogens in hormonal replacement therapy: new molecules, risks, and benefitsMenopause2002961511791081
  • SchmidtIUWakleyGKTurnerRTEffects of estrogen and progesterone on tibia histomorphometry in growing ratsCalcif Tissue Int200067475210908413
  • The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) TrialJAMA19952731992087807658
  • FournierABerrinoFRiboliEAvenelVClavel-ChapelonFBreast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohortInt J Cancer200511444845415551359
  • WrenBGChampionSMWillettsKMangaRZEdenJATransdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal womenMenopause200310131812544672
  • WrenBGMcFarlandKEdwardsLEffect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal womenClimacteric2000315516011910616
  • PanjariMDavisSRDHEA therapy for women: effect on sexual function and wellbeingHum Reprod Update20071323924817208951
  • GenazzaniADLanzoniCGenazzaniARMight DHEA be considered a beneficial replacement therapy in the elderly?Drugs Aging20072417318517362047
  • HydeZFlickerLAlmeidaOPLow free testosterone predicts frailty in older men: the health in men studyJ Clin Endocrinol Metab2010953165317220410223
  • DunnJFNisulaBCRodbardDTransport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasmaJ Clin Endocrinol Metab19815358687195404
  • PardridgeWMSerum bioavailability of sex steroid hormonesClin Endocrinol Metab1986152592783521955
  • LeifkeEGorenoiVWichersCVon Zur MuhlenAVon BurenEBrabantGAge-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohortClin Endocrinol (Oxf)20005368969511155090
  • MorleyJEKimMJHarenMTFrailty and hormonesRev Endocr Metab Disord2005610110815843881
  • WuFCTajarAPyeSRHypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging StudyJ Clin Endocrinol Metab2008932737274518270261
  • LapauwBGoemaereSZmierczakHThe decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changesEur J Endocrinol200815945946818593825
  • SattlerFRCastaneda-SceppaCBinderEFTestosterone and growth hormone improve body composition and muscle performance in older menJ Clin Endocrinol Metab2009941991200119293261
  • StorerTWWoodhouseLMaglianoLChanges in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older menJ Am Geriatr Soc2008561991199918795988
  • HydeZNormanPEFlickerLLow free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men StudyJ Clin Endocrinol Metab20089717918922013106
  • BainJAndropause. Testosterone replacement therapy for aging menCan Fam Physician200147919711212438
  • Emmelot-VonkMHVerhaarHJNakhai PourHREffect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trialJAMA2008299395218167405
  • ChuLWTamSLeePWBioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older menClin Endocrinol (Oxf)20086858959817973937
  • Srinivas-ShankarURobertsSAConnollyMJEffects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled studyJ Clin Endocrinol Metab20109563965020061435
  • KennyAMKleppingerAAnnisKEffects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailtyJ Am Geriatr Soc2010581134114320722847
  • SnyderPJPeacheyHHannoushPEffect of testosterone treatment on bone mineral density in men over 65 years of ageJ Clin Endocrinol Metab1999841966197210372695
  • CherrierMMAsthanaSPlymateSTestosterone supplementation improves spatial and verbal memory in healthy older menNeurology200157808811445632
  • CherrierMMMatsumotoAMAmoryJKTestosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairmentNeurology2005642063206815985573
  • CherrierMMMatsumotoAMAmoryJKCharacterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older menPsychoneuroendocrinology200732727917145137
  • JanowskyJSChavezBOrwollESex steroids modify working memoryJ Cogn Neurosci20001240741410931767
  • JanowskyJSOviattSKOrwollESTestosterone influences spatial cognition in older menBehav Neurosci19941083253328037876
  • LuPHMastermanDAMulnardREffects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly menArch Neurol20066317718516344336
  • TanRSPuSJA pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s diseaseAging Male20036131712809076
  • KennyAMBellantonioSGrumanCAAcostaRDPrestwoodKMEffects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levelsJ Gerontol A Biol Sci Med Sci200257M321M32511983727
  • HydeZNormanPEFlickerLElevated LH predicts ischaemic heart disease events in older men: the Health in Men StudyEur J Endocrinol201116456957721285084
  • YeapBBHydeZNormanPEChubbSAGolledgeJAssociations of total testosterone, sex hormone-binding globulin, calculated free testosterone, and luteinizing hormone with prevalence of abdominal aortic aneurysm in older menJ Clin Endocrinol Metab2010951123113020061425
  • RosanoGMSheibanIMassaroRLow testosterone levels are associated with coronary artery disease in male patients with anginaInt J Impot Res20071917618216943795
  • EnglishKMMandourOSteedsRPDiverMJJonesTHChannerKSMen with coronary artery disease have lower levels of androgens than men with normal coronary angiogramsEur Heart J20002189089410806012
  • YeapBBHydeZAlmeidaOPLower testosterone levels predict incident stroke and transient ischemic attack in older menJ Clin Endocrinol Metab2009942353235919351733
  • OhlssonCBarrett-ConnorEBhasinSHigh serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) Study in SwedenJ Am Coll Cardiol2011581674168121982312
  • LiuPYDeathAKHandelsmanDJAndrogens and cardiovascular diseaseEndocr Rev20032431334012788802
  • RosanoGMLeonardoFPagnottaPAcute anti-ischemic effect of testosterone in men with coronary artery diseaseCirculation1999991666167010190874
  • EnglishKMSteedsRPJonesTHDiverMJChannerKSLow-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled studyCirculation20001021906191111034937
  • BasariaSCovielloADTravisonTGAdverse events associated with testosterone administrationN Engl J Med201036310912220592293
  • VigenRO’DonnellCIBaronAEAssociation of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levelsJAMA20133101829183624193080
  • WaldMMeachamRBRossLSNiederbergerCSTestosterone replacement therapy for older menJ Androl20062712613216474018
  • BhasinSBasariaSDiagnosis and treatment of hypogonadism in menBest Pract Res Clin Endocrinol Metab20112525127021397197
  • NobleRLThe development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administrationCancer Res19773719291933858144
  • PierorazioPMFerrucciLKettermannALongoDLMetterEJCarterHBSerum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of AgingBJU Int201010582482919751256
  • TravisRCKeyTJAllenNESerum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and NutritionInt J Cancer20071211331133817514649
  • RoddamAWAllenNEApplebyPKeyTJEndogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studiesJ Natl Cancer Inst200810017018318230794
  • MorgentalerATestosterone replacement therapy and prostate cancerUrol Clin North Am200734555563 vii17983895
  • KheraMAndrogens and erectile function: a case for early androgen use in postprostatectomy hypogonadal menJ Sex Med20096Suppl. 323423819207279
  • CowardRMSimhanJCarsonCC3rdProstate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapyBJU Int20091031179118319154450
  • RhodenELMorgentalerARisks of testosterone-replacement therapy and recommendations for monitoringN Engl J Med200435048249214749457
  • MoralesALunenfeldBInvestigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging MaleAging Male20025748612198738
  • SarosdyMFTestosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapyCancer200710953654117183557
  • MoralesABlackAMEmersonLETestosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observationsBJU Int2009103626418671790
  • SamarasNFrangosEForsterALangPSamarasDAndropause: a review of the definition and treatmentEur Geriatr Med201236368373
  • SamarasNSamarasDLangPOChronic obstructive pulmonary disease: risk and benefit of testosterone therapyRev Med Suisse201282224222723240298
  • DavisSRPanjariMStanczykFZClinical review: DHEA replacement for postmenopausal womenJ Clin Endocrinol Metab2011961642165321411558
  • PanjariMDavisSRDHEA for postmenopausal women: a review of the evidenceMaturitas20106617217920089375
  • LiuDDillonJSDehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptorSteroids20046927928915183694
  • ValentiGDentiLMaggioMEffect of DHEAS on skeletal muscle over the life span: the InCHIANTI studyJ Gerontol A Biol Sci Med Sci20045946647215123757
  • KostkaTArsacLMPatricotMCBerthouzeSELacourJRBonnefoyMLeg extensor power and dehydroepiandrosterone sulfate, insulin-like growth factor-I and testosterone in healthy active elderly peopleEur J Appl Physiol200082839010879447
  • RavagliaGFortiPMaioliFDeterminants of functional status in healthy Italian nonagenarians and centenarians: a comprehensive functional assessment by the instruments of geriatric practiceJ Am Geriatr Soc199745119612029329480
  • Bischoff-FerrariHAOravEJDawson-HughesBAdditive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and womenOsteoporos Int2008191307131418351428
  • NawataHTanakaSTakayanagiRAromatase in bone cell: association with osteoporosis in postmenopausal womenJ Steroid Biochem Mol Biol1995531651747626449
  • WangLWangYDWangWJZhuYLiDJDehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptorJ Mol Endocrinol20073846747917446236
  • ClarkeBLEbelingPRJonesJDPredictors of bone mineral density in aging healthy men varies by skeletal siteCalcif Tissue Int20027013714511907709
  • Barrett-ConnorEGoodman-GruenDPatayBEndogenous sex hormones and cognitive function in older menJ Clin Endocrinol Metab1999843681368510523014
  • MichaelAJenawayAPaykelESHerbertJAltered salivary dehydroepiandrosterone levels in major depression in adultsBiol Psychiatry20004898999511082473
  • FeldmanHAJohannesCBAraujoABMohrBALongcopeCMcKinlayJBLow dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging StudyAm J Epidemiol2001153798911159150
  • YoshidaSAiharaKAzumaHDehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial functionAtherosclerosis201021231031520627295
  • HerringtonDMDehydroepiandrosterone and coronary atherosclerosisAnn N Y Acad Sci19957742712808597465
  • HerringtonDMNanjeeNAchuffSCCameronDEDobbsBBaughmanKLDehydroepiandrosterone and cardiac allograft vasculopathyJ Heart Lung Transplant19961588938820087
  • NakamuraSYoshimuraMNakayamaMPossible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heartCirculation20041101787179315364798
  • JankowskaEABielBMajdaJAnabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survivalCirculation20061141829183717030678
  • ShufeltCBretskyPAlmeidaCMDHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health–National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE)J Clin Endocrinol Metab2010954985499220739385
  • Barrett-ConnorEKhawKTYenSSA prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular diseaseN Engl J Med1986315151915242946952
  • BasarMMAydinGMertHCRelationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile FunctionUrology20056659760116140085
  • AlexopoulouOJamartJMaiterDErectile dysfunction and lower androgenicity in type 1 diabetic patientsDiabetes Metab20012732933611431598
  • FeldmanHAGoldsteinIHatzichristouDGKraneRJMcKinlayJBImpotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging StudyJ Urol199415154618254833
  • DavisSRDavisonSLDonathSBellRJCirculating androgen levels and self-reported sexual function in womenJAMA2005294919615998895
  • MoralesAJHaubrichRHHwangJYAsakuraHYenSSThe effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and womenClin Endocrinol (Oxf)1998494214329876338
  • VillarealDTHolloszyJOKohrtWMEffects of DHEA replacement on bone mineral density and body composition in elderly women and menClin Endocrinol (Oxf)20005356156811106916
  • VillarealDTHolloszyJOEffect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trialJAMA20042922243224815536111
  • KalmanDSColkerCMSwainMATorinaGCShiQA randomized, double-blind, placebo-controlled study of 3-acetyl–7-oxo-dehydroepiandrosterone in healthy over-weight adultsCurr Ther Res200061435442
  • KennyAMBoxerRSKleppingerABrindisiJFeinnRBurlesonJADehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older womenJ Am Geriatr Soc2010581707171420863330
  • WeissEPShahKFontanaLLambertCPHolloszyJOVillarealDTDehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on boneAm J Clin Nutr2009891459146719321570
  • von MuhlenDLaughlinGAKritz-SilversteinDBergstromJBettencourtREffect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trialOsteoporos Int20081969970718084691
  • JankowskiCMGozanskyWSSchwartzRSEffects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trialJ Clin Endocrinol Metab2006912986299316735495
  • JankowskiCMGozanskyWSKittelsonJMVan PeltRESchwartzRSKohrtWMIncreases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogensJ Clin Endocrinol Metab2008934767477318812486
  • LabrieFDiamondPCusanLGomezJLBelangerACandasBEffect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal womenJ Clin Endocrinol Metab199782349835059329392
  • SunYMaoMSunLFengYYangJShenPTreatment of osteoporosis in men using dehydroepiandrosterone sulfateChin Med J (Engl)200211540240411940375
  • NairKSRizzaRAO’BrienPDHEA in elderly women and DHEA or testosterone in elderly menN Engl J Med20063551647165917050889
  • SchmidtPJDalyRCBlochMDehydroepiandrosterone monotherapy in midlife-onset major and minor depressionArch Gen Psychiatry20056215416215699292
  • WolkowitzOMReusVIKeeblerADouble-blind treatment of major depression with dehydroepiandrosteroneAm J Psychiatry199915664664910200751
  • WolkowitzOMReusVIRobertsEDehydroepiandrosterone (DHEA) treatment of depressionBiol Psychiatry1997413113189024954
  • StrousRDMaayanRLapidusRDehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophreniaArch Gen Psychiatry20036013314112578430
  • BlochMSchmidtPJDanaceauMAAdamsLFRubinowDRDehydroepiandrosterone treatment of midlife dysthymiaBiol Psychiatry1999451533154110376113
  • ReiterWJPychaASchatzlGDehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled studyUrology19995359059410096389
  • BaulieuEEThomasGLegrainSDehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issueProc Natl Acad Sci U S A2000974279428410760294
  • GenazzaniARStomatiMValentinoVEffect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexualityClimacteric20111466166821942655
  • ArltWCalliesFvan VlijmenJCDehydroepiandrosterone replacement in women with adrenal insufficiencyN Engl J Med19993411013102010502590
  • MunarrizRTalakoubLFlahertyEAndrogen replacement therapy with dehydroepiandrosterone for androgen insufficiency and female sexual dysfunction: androgen and questionnaire resultsJ Sex Marital Ther200228Suppl. 116517311898698
  • LabrieFArcherDBouchardCEffect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal womenMenopause20091692393119424093
  • ReiterWJSchatzlGMarkIZeinerAPychaAMarbergerMDehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologiesUrol Res20012927828111585284
  • StomatiMMonteleonePCasarosaESix-month oral dehydroepiandrosterone supplementation in early and late postmenopauseGynecol Endocrinol20001434236311109974
  • LabrieFArcherDBouchardCIntravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophyMenopause20091690792219436225
  • LegrainSMassienCLahlouNDehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjectsJ Clin Endocrinol Metab2000853208321710999810
  • TraishAMKangHPSaadFGuayATDehydroepiandrosterone (DHEA): a precursor steroid or an active hormone in human physiologyJ Sex Med201182960298222032408
  • SchwartzAGPashkoLLCancer prevention with dehydroepiandrosterone and non-androgenic structural analogsJ Cell Biochem Suppl1995222102178538200
  • SchwartzAGPashkoLLDehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevityAgeing Res Rev2004317118715177053
  • AllenNEApplebyPNKaaksRRinaldiSDaveyGKKeyTJLifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British womenCancer Causes Control200314657412708727
  • GiordanoRBonelliLMarinazzoEGhigoEArvatEGrowth hormone treatment in human ageing: benefits and risksHormones (Athens)2008713313918477550
  • GhigoEArvatEGianottiLHuman aging and the GH-IGF-I axisJ Pediatr Endocrinol Metab19969Suppl. 32712788887170
  • HerschECMerriamGRGrowth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus?Clin Interv Aging2008312112918488883
  • BartkeACoschiganoKKopchickJGenes that prolong life: relationships of growth hormone and growth to aging and life spanJ Gerontol A Biol Sci Med Sci200156B340B34911487592
  • HolzenbergerMDupontJDucosBIGF-1 receptor regulates lifespan and resistance to oxidative stress in miceNature200342118218712483226
  • BartkeAMinireview: role of the growth hormone/insulin-like growth factor system in mammalian agingEndocrinology20051463718372315919742
  • Guevara-AguirreJBalasubramanianPGuevara-AguirreMGrowth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humansSci Transl Med2011370ra13
  • LaronZDo deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity?Mech Ageing Dev200512630530715621211
  • Menezes OliveiraJLMarques-SantosCBarreto-FilhoJALack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutationJ Clin Endocrinol Metab2006912093209916522693
  • ShechterMGinsbergSScheinowitzMFeinbergMSLaronZObese adults with primary growth hormone resistance (Laron syndrome) have normal endothelial functionGrowth Horm IGF Res20071716517017320443
  • ShevahOLaronZPatients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary reportGrowth Horm IGF Res200717545717166755
  • BessonASalemiSGallatiSReduced longevity in untreated patients with isolated growth hormone deficiencyJ Clin Endocrinol Metab2003883664366712915652
  • MerriamGRSchwartzRSVitielloMVGrowth hormone-releasing hormone and growth hormone secretagogues in normal agingEndocrine200322414814610297
  • GazzarusoCGolaMKaramouzisIGiubbiniRGiustinaACardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH: an updateJ Clin Endocrinol Metab201499182924217903
  • RuckerDEzzatSDiamandiAKhosraviJHanleyDAIGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling menClin Endocrinol (Oxf)20046049149915049965
  • GillbergPOlofssonHMallminHBlumWFLjunghallSNilssonAGBone mineral density in femoral neck is positively correlated to circulating insulin-like growth factor (IGF)-I and IGF-binding protein (IGFBP)-3 in Swedish menCalcif Tissue Int200270222911907704
  • SchneiderHJPagottoUStallaGKCentral effects of the somatotropic systemEur J Endocrinol200314937739214585082
  • NybergFBurmanPGrowth hormone and its receptors in the central nervous system: location and functional significanceHorm Res19964518228742113
  • KalmijnSJanssenJAPolsHALambertsSWBretelerMMA prospective study on circulating insulin-like growth factor I (IGF-I), IGF-binding proteins, and cognitive function in the elderlyJ Clin Endocrinol Metab2000854551455511134107
  • RolleroAMurialdoGFonziSRelationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjectsNeuropsychobiology19983873799732206
  • PapadakisMAGradyDBlackDGrowth hormone replacement in healthy older men improves body composition but not functional abilityAnn Intern Med19961247087168633830
  • FrancoCBrandbergJLonnLAnderssonBBengtssonBAJohannssonGGrowth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a. 12-month placebo-controlled trialJ Clin Endocrinol Metab2005901466147415598680
  • LangeKHAndersenJLBeyerNGH administration changes myosin heavy chain isoforms in skeletal muscle but does not augment muscle strength or hypertrophy, either alone or combined with resistance exercise training in healthy elderly menJ Clin Endocrinol Metab20028751352311836279
  • de BoerHBlokGJVan der VeenEAClinical aspects of growth hormone deficiency in adultsEndocr Rev19951663867758433
  • LiuHBravataDMOlkinISystematic review: the safety and efficacy of growth hormone in the healthy elderlyAnn Intern Med200714610411517227934
  • CarroETrejoJLGerberATherapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosisNeurobiol Aging2006271250125716183170
  • VitielloMVMoeKEMerriamGRMazzoniGBuchnerDHSchwartzRSGrowth hormone releasing hormone improves the cognition of healthy older adultsNeurobiol Aging20062731832316399214
  • SathiavageeswaranMBurmanPLawrenceDEffects of GH on cognitive function in elderly patients with adult-onset GH deficiency: a placebo-controlled 12-month studyEur J Endocrinol200715643944717389458
  • BanerjeeIClaytonPEGrowth hormone treatment and cancer riskEndocrinol Metab Clin North Am20073624726317336744
  • BartkeAGrowth hormone and aging: a challenging controversyClin Interv Aging2008365966519281058